CRL vs EXEL · rev $2.00B vs P/E 17, rev $628.7M
Charles River Laboratories (CRL) versus Exelixis Inc (EXEL) — a side-by-side from cached financials, not a winner call.
Charles River Laboratories (CRL) is a diagnostics & research company listed on US.
Exelixis Inc (EXEL) is a biotechnology company listed on US.
Latest reported CRL revenue for 2026-06-27 was $2.00B. Net income was -$16.3M. CRL currently screens at market cap $7.78B.
Latest reported EXEL revenue for 2026-07-03 was $628.7M. Net income was $212.1M. Revenue was up 2.9% from 2026-04-03 to 2026-07-03. EXEL currently screens at market cap $12.69B and trailing P/E 16.7.
CRL currently screens at market cap $7.78B. EXEL currently screens at market cap $12.69B and trailing P/E 16.7.
Not investment advice. Open the CRL and EXEL stock pages for the full models.
Not investment advice.